7Baggers
 press release: inhibrx reports third quarter 2025 financial results  富途牛牛 Sat, 15 Nov 2025 21:09:10 GMT
 inhibrx biosciences shares surge on clinical breakthrough  AD HOC NEWS Sat, 15 Nov 2025 17:42:04 GMT
 Inhibrx options imply 7.3% move in share price post-earnings  TipRanks Fri, 14 Nov 2025 19:31:58 GMT
 Inhibrx Misses Estimates Even As New Cancer Drug Shows Promise  Finimize Fri, 14 Nov 2025 15:47:28 GMT
 earnings flash (inbx) inhibrx biosciences posts q3 loss $2.28 a share  MarketScreener Fri, 14 Nov 2025 11:22:37 GMT
 Inhibrx Biosciences' Q3 net loss widens, misses EPS estimates  MarketScreener Fri, 14 Nov 2025 11:13:01 GMT
 Inhibrx Biosciences, Inc. SEC 10-Q Report  TradingView Fri, 14 Nov 2025 11:13:00 GMT
 Inhibrx Reports Third Quarter 2025 Financial Results  PR Newswire Fri, 14 Nov 2025 11:00:00 GMT
 Press Release: Inhibrx Reports Third Quarter 2025 Financial Results  富途牛牛 Fri, 14 Nov 2025 11:00:00 GMT
 Inhibrx supports CTOS2025 spotlight on chondrosarcoma  Traders Union Wed, 12 Nov 2025 00:57:01 GMT
 published on: 2025-11-05 09:59:43  newser.com Wed, 05 Nov 2025 15:59:43 GMT
 Inhibrx Announces Participation in Upcoming Scientific Conferences  PR Newswire Tue, 04 Nov 2025 08:00:00 GMT
 published on: 2025-11-03 05:26:29  newser.com Mon, 03 Nov 2025 11:26:29 GMT
 ethic inc. purchases new shares in inhibrx biosciences, inc. $inbx  MarketBeat Sat, 01 Nov 2025 07:53:03 GMT
 Inhibrx Biosciences stock hits all-time high of 83.93 USD  Investing.com Fri, 31 Oct 2025 07:00:00 GMT
 inhibrx biosciences (nasdaq:inbx) trading up 7.8% - what's next?  MarketBeat Thu, 30 Oct 2025 16:38:14 GMT
 published on: 2025-10-30 02:27:04  newser.com Thu, 30 Oct 2025 07:27:04 GMT
 published on: 2025-10-28 03:10:26  newser.com Tue, 28 Oct 2025 08:10:26 GMT
 published on: 2025-10-28 00:45:26  newser.com Tue, 28 Oct 2025 05:45:26 GMT
 published on: 2025-10-27 17:56:12  newser.com Mon, 27 Oct 2025 22:56:12 GMT
 published on: 2025-10-27 16:02:36  newser.com Mon, 27 Oct 2025 21:02:36 GMT
 inhibrx preps us filing for ozekibart in rare bone cancer after phase ii win  Citeline News & Insights Mon, 27 Oct 2025 07:24:03 GMT
 published on: 2025-10-26 03:33:26  newser.com Sun, 26 Oct 2025 08:33:26 GMT
 published on: 2025-10-25 20:36:05  newser.com Sun, 26 Oct 2025 01:36:05 GMT
 published on: 2025-10-25 14:49:36  newser.com Sat, 25 Oct 2025 19:49:36 GMT
 inhibrx biosciences (nasdaq:inbx) shares gap up - still a buy?  MarketBeat Sat, 25 Oct 2025 07:00:00 GMT

Inhibrx, Inc
(NASDAQ:INBX) 

INBX stock logo

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Its therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 1 clinical trials in patients with solid tumors, including sarc...

Founded: 2010
Full Time Employees: 75
CEO: Mark P. Lappe  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends